Body weight and biochemical parameters
- 3-hour food deprivation
A nutrional animal model with a "human-like" lipoprotein profile to evaluate your compounds affecting both diabetes and dyslipidemia
Key benefits
- To test drugs affecting both diabetes and dyslipidemia in an obese, insulin resistant and dyslipidemic model.
- A model specifically designed to perform the most predictive in vivo experiments: euglycemic hyperinsulinemic clamp, in vivo macrophage-to-feces reverse cholesterol transport and LDL/HDL kinetics.
Animal Model
- Background strain: C57BL6/J mouse carrying both human CETP and human apoB100
- Gender/age: male, 6-week old
- Diet: 60% high fat diet
- Time on diet: 3 months
- Positive reference compounds: torcetrapib, metformin, sitagliptin
Pathophysiological features and scientific data
Torcetrapib increases HDL cholesterol.
- Body weight and biochemical parameters
- Overnight fasting
- Lipoprotein/apolipoprotein profile and CETP activity
- 3-hour food deprivation
- 3-hour food deprivation
Torcetrapib improves macrophage-to-feces reverse cholesterol transport.
- Macrophage-to-feces reverse cholesterol transport
Both sitagliptin and metformin improve glucose homeostasis.
- Oral glucose tolerance test
Cholesterol mass excreted in feces increases in sitagliptin treated mice.
- Cholesterol mass excreted in feces
Sitagliptin improves macrophage-to-feces RCT through reduced intestinal cholesterol absorption.
- Macrophage-to-feces reverse cholesterol transport
- Intestinal cholesterol absorption
Add on studies
References and publications
- Briand F. et al. DPP-4 inhibitor sitagliptin improves reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Presented as a poster during the 71st American Diabetes Association meeting 2011.